Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.

[1]  Xiaozhen Liu,et al.  EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies , 2019, International journal of cancer.

[2]  Sung Sook Lee,et al.  Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  M. Ahn.  Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation? , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  M. Kris,et al.  Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. , 2019 .

[5]  J. Suri,et al.  Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features , 2019, Cancers.

[6]  Yuan Luo,et al.  Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice , 2019, Radiation Research.

[7]  Tetsuya Tanimoto,et al.  EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[8]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[9]  In Seok Yang,et al.  Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. , 2017, Lung cancer.

[10]  N. Hamada,et al.  Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice. , 2017, Biochemical and biophysical research communications.

[11]  E. Felip,et al.  Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. , 2017, Lung cancer.

[12]  J. Ahn,et al.  EGFR TKI combination with immunotherapy in non-small cell lung cancer , 2017, Expert opinion on drug safety.

[13]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[14]  C. Rudin,et al.  441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC , 2016 .

[15]  S. Yuspa,et al.  Cell autonomous or systemic EGFR blockade alters the immune‐environment in squamous cell carcinomas , 2016, International journal of cancer.

[16]  Haiyi Jiang,et al.  Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  M. Ahn,et al.  Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  S. Holdsworth,et al.  Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase , 2016, Journal of immunology research.

[19]  R. Sullivan,et al.  Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. , 2015, Seminars in oncology.

[20]  Y. Huang,et al.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[22]  W. Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[23]  S. Gettinger,et al.  Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. , 2014 .

[24]  M. Meyerson,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[25]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[26]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[27]  A. Gemma,et al.  F1000 highlights , 2010 .

[28]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.